Goal
The goal of this course is to equip the cardio-oncology community with practical scientific knowledge fostering the progression of patient-centered, evidence-based, collaborative cardiovascular and cancer care for patients living with and beyond cancer.

Learning Objectives
Upon completion of this educational activity, participants will be able to:

1. Identify the oncologic indications, mechanisms of action, and cardiotoxicity risk of specific therapies that comprise the pillars of cancer treatment such as chemotherapy, immune therapy, targeted therapy, and radiation.
2. Define the evidence supporting clinical, imaging, and biomarker-guideline recommendations regarding risk stratification and monitoring strategies in cancer patients treated with potentially cardiotoxic therapies, with a focus on practical applications.
3. Apply evidence-based pharmacologic and non-pharmacologic strategies to mitigate and actively manage the short- and long-term cardiotoxicity risk in patients living with and beyond cancer.
4. Recognize the mechanistic and epidemiologic overlap between cancer and cardiovascular disease, going beyond the cardiotoxicity of cancer therapies to understand their broader impact on health.
5. Describe the impact of health disparities, genomic ancestry, and social determinants of health in cardiovascular disease in patients living with and beyond cancer.
6. Analyze strategies for patient education and communication to enhance understanding and management of cardiotoxicity risks associated with cancer therapies.
7. Design a multi-disciplinary, interprofessional cardio-oncology care team and successful framework to advance the overall cardiovascular care of cancer patients and survivors.
8. Evaluate the pathophysiologic basis of amyloidosis, as well as current diagnostic and treatment strategies.

Target Audience
The primary target audience is cardiologists, internists, pharmacists, nurses, trainees, and all members of the interprofessional care team who advance the clinical care of, and conduct clinical research that is relevant to, the growing population of cancer patients and survivors at risk for, or suffer from, cardiovascular disease.

Course Chair

Richard Cheng, MD, MSc FACC
Professor of Cardiology; Program Director for the Advanced Heart Failure Training Fellowship; Section Head for Heart Failure, MCS, Heart Transplant and Cardio-oncology at University of Washington

Course Vice Chair

Anju Nohria, MD, MSc
Assistant Professor of Medicine at Harvard Medical School, Director of the Cardio-Oncology Program at Dana-Farber Brigham Cancer Center and Brigham and Women's Hospital

Planning Committee

Alana M. Ferrari, PharmD
Hematology/Oncology Clinical Pharmacist at University of Virginia

Jacqueline B. Vo, PhD, RN, MPH
Tenure-Track Investigator at Division of Cancer Epidemiology & Genetics, National Cancer Institute

Teresa Lopez-Fernandez, MD
Clinical Investigator at La Paz University

To Register online click the Register button at the top of the page or call ACC Member Care at 800-253-4636 or 202-375-6000.

Registration Fees

To register for in-person participation, click here.

Cancellations
Cancellation, substitution, or transfer to another course is allowed if written notification is received four weeks before a scheduled course. A full refund minus a $149 processing fee will be given for written notifications received fewer than four weeks before the first day of the course. No refund will be given for no-shows.

ACC reserves the right to cancel the course in the unlikely event of insufficient enrollment or other unforeseen circumstances. If a course is canceled or postponed, ACC will refund registration tuition but cannot be held responsible for other costs or expenses, including cancellation/change penalties assessed by airlines, travel agencies or hotels.

We invite you to submit an abstract or case for the upcoming Advancing the Cardiovascular Care of the Oncology Patient course. The submission portal will open in mid-October. Authors of selected abstracts and cases will be invited to present their work in person at Heart House during the course. Upon notification of acceptance, these authors will receive special instructions for registration.

Before submitting your abstract or case, please carefully review the abstract policies and submission instructions provided below.

• Abstract Policies and Procedures
• Abstract Submission Instructions

Submissions are welcomed in the following categories:

• Clinical Case Challenge: Patient case presentation
• Original Research Abstracts
  • Basic Science in Cardio-Oncology (fundamental or bench research)
  • Translational Science in Cardio-Oncology (translating basic science to potential treatment)
  • Clinical Science in Cardio-Oncology (collection of evidence to establish treatment)
  • Implementation Science (application of research into practice/policy)
• Professional Development Abstracts
  • Training and Education in Cardio-Oncology (training curriculum or best practices)
  • ACC Cardio-Oncology Section Activities (member activities and outreach)
  • Feature Your Cardio-Oncology Clinical Program (establishment and expansion of program)

Contact ACCeducation@acc.org with questions.

An important part of the Advancing the Cardiovascular Care of the Oncology Patient experience remains the exhibits and industry sponsored reception. Both opportunities offer the chance for face-to-face networking with all attendees during dedicated times in the program. Learn more about the opportunities available in the Exhibitor Prospectus.